Here are just three known gene editing stocks that are about to explode during the 5G revolution, which one should you buy out of Crispr Therapeutics (CRISPR), Intellia Therapeutics (NTLA) and Editas Medicine (EDIT)? Today, we find out!
Gene Editing
Gene editing is also called as genome editing in which replacement, placing, and removal of chemical-based pairs are constructed in Gene editing procedure. The functions of an organism are impacted due to the changes in DNA base pairs. Commonly gene-editing therapies are conveyed by means of a virus, which is named as a viral vector.
Crispr Therapeutics (CRISPR)
Crispr Therapeutics developed a method to edit genomes of living organisms that can be changed and is known as Crispr. Basically, it is a good bacterial (CRISPR cas9) antivirus defense system. The simplified version of the bacterial CRISPR antivirus defense system is a base of CRISPR which enables Crispr to edit genomes. CRISPR also enables scientists to cut and paste genes into DNA in a short time period.
A term that explains nucleic acid family sequences, which were exposed in Archaea and Bacteria. These archaea and bacteria contained several virus genes. It looked like these organisms had stolen genes from viruses in some way. Scientists wanted to know the reason behind it. If whenever archaea and bacteria are infected by the virus, enzymes associated with CRISPR will find and break infected nucleic acid identifying by the code.
It will also destroy, some most fatal viruses found in the CRISPR library, this capability to find definite DNA sequences accurately and break these sequences is familiar as a wonderful tool for gene editing.
A protein known as CAS9 is used in conjunction with engineered CRISPR sequences to find out genetic codes and piece them together like a molecular scalpel and allows to cut a specific gene.
It also allows you to eliminate or change it with a new sequence. CRISPR technology was used in the past few years to get rid of genes that cause diseases. It was also used to wipe out drug-resistant super bugs and has been applied to create molecular recording devices in the past few years.
Intellia Therapeutics (NTLA)
Intellia therapeutics is a Biotechnology Company that develops bio-pharmaceuticals. Intellia therapeutics uses the CRISPR gene editing system. This CRISPR gene editing system was discovered by Jennifer Doudna and Virginijus Šikšnys. Regeneron is working in partnership with the Intellia for the ATTR program.
These both secure authority to license for 9 other targets of Intellia’s CRISPR therapies. Further, Regeneron empowered Intellia with a $50 million dollar investment.
Intellia joined Novartis in 2015 and are both struggling to get progress in developing CRISPR gene editing therapies to target Sequential Compression Device (SCD) and some other hidden cancer symptoms. Novartis owns just about 10% of Intellia.
Editas Medicine (EDIT)
Editas Medicine is a genome editing company. Editas Medicine Company treats patients of genetic diseases. It treats patients by correcting genes that become the reason of disease.
Like Intellia Therapeutics, it also uses CRISPR gene editing. EDIT 101 is a lead candidate. Its target is to treat Leber congenital type 10, which is the main causes of genetic blindness.
According to Katrine Bosley, CEO of Editas, EDIT 101 is to be 1st in Vivo CRISPR therapy which is coming very soon and will be tested in human beings. Editas planned to start screening patients for phase ½ clinical studies in the 1st half of the following year of 2019.
After the screening of the patients in the 1st half, Editas planned to start dosing patients in the 2nd half of 2019. Editas is not only going with EDIT 101 but also with Allergan since 2017. This secures the license to almost 4 other gene-editing therapies. These four other gene-editing therapies are aimed at eye diseases.
Which should you buy?
We described the above three gene-editing methods. From the most recent results, it is cleared that you should buy Crispr Therapeutics as it is currently the best gene-editing method as compared to Intellia Therapeutics and Editas Medicine.
Intellia Therapeutics and Editas Medicine also work on the rules of CRISPR. Crispr stocks are increasing nowadays because CRISPR offered a first-ever clinical update for sickle cell disease, transfusion-dependent beta-thalassemia, and their lead drug candidate.
Recent results show the share of CRISPR therapeutics up 26% which are more than the shares of Editas Medicine and Intellia Therapeutics. The share of Intellia Therapeutics is up 17.4% and the shares of Editas Medicine are up 16.9%.
